Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis
Authors
Bradley J. Monk (ORCID: https://orcid.org/0000-0001-6985-0159)
Cumhur Tekin (ORCID: https://orcid.org/0009-0003-9579-2935)
M. Valeria Cáceres (ORCID: https://orcid.org/0009-0006-7115-7226)
C. Dubot (ORCID: https://orcid.org/0009-0006-6550-9432)
Se Ik Kim (ORCID: https://orcid.org/0000-0002-9790-6735)
Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis
Bradley J. Monk, Cumhur Tekin, M. Valeria Cáceres, C. Dubot et al.
Citations
1 citations
Journal
Journal of Gynecologic Oncology
Topics
Cervical Cancer and HPV Research
Field-Weighted Citation Impact (FWCI)
1.35
article
Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis
Bradley J. Monk, Cumhur Tekin, M. Valeria Cáceres, C. Dubot, Se Ik Kim, Shin Nishio, Krishnansu S. Tewari, Domenica Lorusso, Kosei Hasegawa, Kan Li, Jeong‐Won Lee, Nicoletta Colombo, Yong-Man Kim, Wen‐Shiung Liou
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Journal of Gynecologic OncologyVol. 36(4)
Institutions
Kurume University (JP), Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Humanitas University (IT), Seoul National University (KR), University of California, Irvine (US), Asan Medical Center (KR), Samsung Medical Center (KR), University of Ulsan (KR), Hôpital René Huguenin (FR), Florida Cancer Specialists & Research Institute (US), Kaohsiung Veterans General Hospital (TW), Instituto de Oncología de Rosario (AR), IRCCS Humanitas Research Hospital (IT), European Institute of Oncology (IT), University of Milano-Bicocca (IT), Sungkyunkwan University (KR), Saitama Medical University (JP)